Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:32:50 EDT Mon 11 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:TRDA - ENTRADA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TRDA - Q7.46.30·7.006.66.841.3430    16.45  4.9308:07:13May 0715 min RT 2¢

Recent Trades - Last 10 of 30
Time ETExPriceChangeVolume
08:07:13Q6.900.0615
07:57:44Q6.900.061
07:49:39Q6.900.0623
07:29:23Q6.870.0310
07:29:23Q6.83-0.018
07:29:23Q6.82-0.0267
07:29:23Q6.73-0.113
07:29:23Q6.80-0.041
07:29:23Q6.910.0710
07:29:23Q6.910.0710

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-07 07:10U:TRDANews ReleaseEntrada Therapeutics Reports First Quarter 2026 Financial Results
2026-05-07 07:00U:TRDANews ReleaseEntrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
2026-05-06 16:30U:TRDANews ReleaseEntrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
2026-03-02 16:30U:TRDANews ReleaseEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-26 07:00U:TRDANews ReleaseEntrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-17 07:00U:TRDANews ReleaseIndependent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
2026-02-04 07:00U:TRDANews ReleaseEntrada Therapeutics to Present at Upcoming Investor Conferences
2026-01-08 07:00U:TRDANews ReleaseEntrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
2025-12-17 07:00U:TRDANews ReleaseEntrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-04 16:30U:TRDANews ReleaseEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-06 07:00U:TRDANews ReleaseEntrada Therapeutics Reports Third Quarter 2025 Financial Results
2025-10-28 07:00U:TRDANews ReleaseEntrada Therapeutics to Present at Upcoming Investor Conferences
2025-09-05 07:00U:TRDANews ReleaseEntrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
2025-09-02 16:30U:TRDANews ReleaseEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-06 07:00U:TRDANews ReleaseEntrada Therapeutics Reports Second Quarter 2025 Financial Results
2025-06-03 07:00U:TRDANews ReleaseEntrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
2025-06-02 16:30U:TRDANews ReleaseEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-28 07:00U:TRDANews ReleaseEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping